Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eudra GMP database now publicly available

This article was originally published in The Gold Sheet

Executive Summary

EMEA announced that the Eudra GMP database became publicly available on Aug. 1. The database includes manufacturing authorizations approved and GMP certificates issued by competent authorities, as well as manufacturers that have not complied with GMPs. Non-compliance statements are issued in cases of severe GMP infractions. The Eudra GMP database was initially launched in April 2007 to facilitate the exchange of information on compliance with GMPs between EU competent authorities. EMEA said that the database was launched in a drive for more openness and transparency. Commercial, personal and other types of confidential information will not be publicly available. The database will be updated by competent authorities on an ongoing basis. EMEA announced that "for some competent authorities, the publicly available information in the database is limited at this time.

You may also be interested in...



Publisher's Spotlight: Clinical And Research Excellence Honored At The Citeline Awards

Informa Pharma Intelligence congratulates the winners of the fifth annual awards. 

Publisher's Spotlight: Clinical And Research Excellence Honored At The Citeline Awards

Informa Pharma Intelligence congratulates the winners of the fifth annual awards. 

Ultragenyx Enters Duchenne Gene Therapy Space In $295m Deal With Solid Biosciences

Ultragenyx enters a competitive and complicated market, but the combination of its manufacturing platform with Solid’s transgene could provide an advantage. 

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel